Literature DB >> 16236088

Is Europe ready to embrace a policy of universal varicella vaccination?

J Ramet1, C Weil-Olivier, W Sedlak.   

Abstract

For the first time, a live attenuated varicella vaccine with an indication for universal vaccination is licensed in all EU countries. It is now time to consider whether in Europe there should be widespread vaccination against varicella to prevent this common and highly infectious disease. Increasing numbers of countries are adopting vaccination programmes against the disease. In those countries where a routine vaccination policy has been adopted, the success of the vaccine has been significant. The USA, which prior to the launch of a universal vaccination programme in 1995 had 4 million cases of varicella per year, has seen a dramatic reduction in varicella morbidity and mortality rates. A universal varicella vaccination policy is an option that needs to be considered for Europe not only in medical terms but also because it would be socially and economically appropriate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236088     DOI: 10.1111/j.1742-1241.2005.00647.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  5 in total

Review 1.  Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.

Authors:  Oliver Damm; Bernhard Ultsch; Johannes Horn; Rafael T Mikolajczyk; Wolfgang Greiner; Ole Wichmann
Journal:  BMC Public Health       Date:  2015-06-05       Impact factor: 3.295

2.  The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.

Authors:  Christophe Sauboin; Katsiaryna Holl; Paolo Bonanni; Anne A Gershon; Bernd Benninghoff; Stephane Carryn; Margaret A Burgess; Peter Wutzler
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.667

3.  Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.

Authors:  Ellen Wolff; Katarina Widgren; Gianpaolo Scalia Tomba; Adam Roth; Tiia Lep; Sören Andersson
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

Review 4.  Varicella vaccination in Europe - taking the practical approach.

Authors:  Paolo Bonanni; Judith Breuer; Anne Gershon; Michael Gershon; Waleria Hryniewicz; Vana Papaevangelou; Bernard Rentier; Hans Rümke; Catherine Sadzot-Delvaux; Jacques Senterre; Catherine Weil-Olivier; Peter Wutzler
Journal:  BMC Med       Date:  2009-05-28       Impact factor: 8.775

5.  Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.

Authors:  Yves Gillet; Pirmin Habermehl; Stéphane Thomas; Cécile Eymin; Anne Fiquet
Journal:  BMC Med       Date:  2009-04-14       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.